ZURICH & BARCELONA - 16 April 2026 – AYUN, Switzerland’s center for advanced longevity, and Omniscope, a pioneer in computational immunology, today announced a strategic partnership to bring the next generation of personalized medicine to Zurich. By combining high-resolution immune sequencing with Generative AI, the partnership allows individuals to create a "Cellular Avatar": a digital model of their immune system used to predict health trends and personalize treatments with unprecedented accuracy.
Modeling the Biological Self: The Cellular Avatar
At the heart of this collaboration isOmniscope’s ability to move beyond traditional, static blood tests. By utilizing GenAI to model the complex architecture of the immune system, the osLifetime platform creates a dynamic "Cellular Avatar" for every client.
This Cellular Avatar allows clinicians to simulate how a person’s body might respond to environmental stressors, aging, or specific medical interventions. By decoding the immune repertoire, the platform provides a predictive lens through which AYUN can tailor personalized treatments, ensuring that every protocol is optimized for the client’s unique biological signature.
A New Era of Precision
"Think of your immune system as your body's most sophisticated internal sensor, constantly reacting to everything from the food you eat to the way you age," says Vijay Vaswani, CEO of Omniscope. "Until now, we couldn't read that data. With osLifetime, we are finally giving people a clear 'dashboard' for their health. We aren't just looking for problems; we’re giving you the tools to fine-tune your body’s natural defenses so you can stay at your peak for longer."
Premier Launch at AYUN Zurich
As a premier partner for Omniscope in Switzerland, AYUN is among the first to integrate this technology into a clinical setting. Starting this month, a select cohort of AYUN clients will begin Phase I of the rollout, establishing their baseline immune models andbeginning the process of longitudinal tracking.
“At AYUN, we believe that truly personalized medicine begins with understanding each individual’s biology at the deepest level,” says Nadine Rapp-Guirey, CMO of AYUN. Integrating Omniscope’s immune sequencing and AI-driven modelling into our clinical practice further elevates our ability todeliver highly individualized care, adding a predictive layer to our already personalized approach. For our clients, this represents a new level of precision in how health can be understood and optimized.
Accessing the Technology
The osLifetime platform is now available to clients at AYUN’s Zurich facility. Individuals looking to establish their Cellular Avatar and engage in longitudinal immune monitoring are encouraged to book a consultation via AYUN’s digital portal.
For more information on the partnership and technology, please visit www.ayun.ch or www.omniscope.ai.
ABOUT OMNISCOPE:
Omniscope is a techbio company building the world’s most advanced immune intelligence platform. Originating from clinical immunology, Omniscope combines patented laboratory technologies, deep T and B cell receptor sequencing, and AI-driven models to generate high-resolution, dynamic insights into the immune system. Omniscope’s mission is to empower clinicians, researchers, and athletes with predictive, personalized immune data — improving diagnostics, therapeutic development, performance, and healthspan. Learn more: https://www.omniscope.ai/about-us
ABOUT AYUN:
AYUN is Switzerland’s premier center for advanced longevity, located in Zurich. Combining cutting-edge diagnostics, personalized treatment protocols, and science-led interventions, AYUN empowers clients to optimize their health and sustain peak performance across every stage of life. AYUN’s mission is to redefine what it means to age well by integrating the latest advances in precision medicine, biomarker analysis, and regenerative health —delivering outcomes that are as individual as the people it serves.
